Valneva SE (VALN) Cash from Financing Activities (2021 - 2026)
Valneva SE (VALN) posted Cash from Financing Activities of -$5.5 million for Q1 2026, up 49.64% sequentially from -$10.9 million in Q4 2025, and up 6.51% YoY from -$5.2 million in Q1 2025.
Valneva SE (VALN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Valneva SE has reported Cash from Financing Activities for 6 years, with the latest figure at -$5.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 6.51% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195032.3 (down 100.54% YoY) and the FY2025 annual result came in at -$722871.0, down 102.18% from the prior year.
- Cash from Financing Activities grew to -$5.5 million in Q1 2026 per VALN's latest filing, from -$10.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.3 billion in Q3 2023 and troughed at -$10.3 billion in Q2 2023.
- A 5-year average of $18.7 million and a median of -$649994.6 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 61612.28% in 2023, down 9392.38% in 2023.
- Over 5 years, Cash from Financing Activities stood at $95.4 million in 2022, then sank by 58.32% to $39.7 million in 2023, then sank by 112.34% to -$4.9 million in 2024, then tumbled by 122.23% to -$10.9 million in 2025, then soared by 49.64% to -$5.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.5 million, -$10.9 million, and -$649994.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 33.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.92 Mn |
| Jun 30, 2026 | 33.92 Mn |
| Mar 31, 2026 | -5.49 Mn |
| Mar 31, 2026 | -5.49 Mn |
| Dec 31, 2025 | -10.90 Mn |
| Dec 31, 2025 | -10.90 Mn |
| Sep 30, 2025 | -649,994.63 |
| Sep 30, 2025 | -649,994.63 |
| Jun 30, 2025 | 16.84 Mn |
| Jun 30, 2025 | 16.84 Mn |
| Mar 31, 2025 | -5.87 Mn |
| Mar 31, 2025 | -5.87 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | 56.95 Mn |
| Sep 30, 2024 | 56.95 Mn |
| Jun 30, 2024 | -9.83 Mn |
| Jun 30, 2024 | -9.83 Mn |
| Mar 31, 2024 | -8.10 Mn |
| Mar 31, 2024 | -8.10 Mn |